FTC Orders Baxter to Divest Rights to Two Drugs as Part of Claris Takeover

Drug Industry Daily
A A
Baxter International will divest the rights to two drugs held by Claris Lifesciences to offset the anticompetitive effects of its acquisition of Claris, under terms of a final FTC order.

To View This Article:

Login

Subscribe To Drug Industry Daily